Anti-Human HLA-DR Antibody (L243) – APC
Product Benefits:
ichorbio’s Anti-Human HLA-DR Antibody (L243) – APC is manufactured in a cGMP compliant facility. ichorbio offers Amazon vouchers or donations to the NC3Rs for reviews of this product: click here for more information.
Target:
HLA-DR
Clone:
L243
Isotype:
Mouse IgG2a
Other Names:
Major Histocompatibility Class II, MHC class II, HLA-DR Monomorphic
Host:
Mouse
Species Reactivity:
Human
Specificity:
Anti-Human HLA-DR Antibody (L243) – APC recognizes/reacts with the HLA-DR antigen, a member of MHC class II molecules. It does not cross-react with HLA-DP and HLA-DQ
Purification Method:
This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.
Antigen Distribution:
The HLA-DR antigen is present on B-lymphocytes, activated T-lymphocytes and activated natural killer (NK) lymphocytes. This antigen is also expressed on monocytes, macrophages, human progenitor cells and B-cell lymphomas.
Background:
HLA-DR is a heterodimeric cell surface glycoprotein comprised of a 36 kD (heavy) chain & a 27 kD (light) chain. It is expressed on B cells, activated T cells, monocytes/macrophages, and dendritic cells. HLA-DR is critical for efficient peptide presentation to CD4+ T cells. Clone L243 binds a conformational epitope on HLA-DRalpha which depends on the correct folding of the Aβ heterodimer.
Immunogen:
Unknown
Concentration:
0.1 mg/ml
Formulation:
This Allophycocyanin (APC) antibody is formulated in 0.01 M phosphate buffered saline (PBS) pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Storage:
This APC antibody is stable when stored at 2-8°C. Do not freeze.
Applications:
Flow Cytometry
Application Notes:
Flow Cytometry: This antibody can be used at a concentration of ≤ 0.25 µg per 100 µl of whole blood (or per 1.0 x 10^6 cells in a 100 µl total staining volume).
Use:
Products are for research use only. Not for use in diagnostic or therapeutic procedures.
Reviews
There are no reviews yet.